Atossa Therapeutics, Inc.ATOS
Price (close)
$1.90
Market cap
$19.0M
P/E
—
Revenue (TTM)
—
Net income
-$37.7M
Dividend yield
—
1-year total return
-84.6%
Net margin
—
Revenue growth
—
Debt / equity
—
What Atossa Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$17.8M | -$20.6M | -$27.0M | -$30.1M | -$25.5M | -$34.8M |
| Free cash flow | -$11.6M | -$16.5M | -$20.8M | -$21.0M | -$21.0M | -$29.8M |
More on ATOS.
- Atossa Therapeutics, Inc. summary
- Atossa Therapeutics, Inc. financial statements
- Atossa Therapeutics, Inc. key metrics
- Atossa Therapeutics, Inc. health scores and style box
- Atossa Therapeutics, Inc. earnings
- Atossa Therapeutics, Inc. dividends
- Atossa Therapeutics, Inc. valuation
- Atossa Therapeutics, Inc. ownership and insiders
- Atossa Therapeutics, Inc. peers
Figures from Atossa Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.